Why the study?
Does spironolactone reduce death in patients with heart failure?
Does spironolactone reduce death in patients with heart failure?
Highlights the significant mortality benefit of adding the aldosterone antagonist spironolactone to standard medical therapy in patients with heart failure.
Supports mortality reduction with subhemodynamic spironolactone in HF; leaves open confirmation in contemporary RCTs.
Understanding of the role, triggers, and impact of the renin-angiotensin-aldosterone system in cardiovascular disease has significantly broadened. In recent years substantial discoveries have been made regarding the pathophysiology of heart failure, particularly in the area of neurohormonal activation. New interest in therapy with aldosterone antagonists was stimulated by results of a 2-year study of 1663 patients with heart failure that showed a 30% relative risk reduction of death among patients given a subhemodynamic dosage of spironolactone, a nonselective aldosterone antagonist, compared with placebo, in addition to standard therapy of diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and digitalis.
No takes yet. Share an insight, caveat, or question.
J. et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: